-
Mashup Score: 0
EAU 2022 combination neoadjuvant hormonal therapy for high-risk prostate cancer, results of ARNEO, a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1
EAU 2022 ARNEO trial, the results of ARNEO, a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk #ProstateCancer. Presentation by @joniau @UZLeuven. #EAU22 written coverage by @zklaassen_md @GACancerCenter > https://t.co/IXQOND96Rm @Uroweb https://t.co/LIeQoyTEwq
-
Discussion: #ARNEO - a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk #ProstateCancer. Presentation by @delataillealex @UrologieMondor. #EUA22 coverage by @zklaassen_md > https://t.co/Zn55UFPLuv @Uroweb https://t.co/VqbAO15gzc